A Critical Overview of Targeted Therapies for Vestibular Schwannoma

被引:22
|
作者
Tamura, Ryota [1 ]
Toda, Masahiro [1 ]
机构
[1] Keio Univ, Dept Neurosurg, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
关键词
schwannoma; NF2; bevacizumab; VEGF; SH3PXD2A-HTRA1; fusion; molecular targeted therapy; NEUROFIBROMATOSIS TYPE-2; TUMOR-SUPPRESSOR; PHASE-II; GROWTH; BEVACIZUMAB; ACTIVATION; EVEROLIMUS; INHIBITION; EXPRESSION; MERLIN;
D O I
10.3390/ijms23105462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vestibular schwannoma (VS) is a benign tumor that originates from Schwann cells in the vestibular component. Surgical treatment for VS has gradually declined over the past few decades, especially for small tumors. Gamma knife radiosurgery has become an accepted treatment for VS, with a high rate of tumor control. For neurofibromatosis type 2 (NF2)-associated VS resistant to radiotherapy, vascular endothelial growth factor (VEGF)-A/VEGF receptor (VEGFR)-targeted therapy (e.g., bevacizumab) may become the first-line therapy. Recently, a clinical trial using a VEGFR1/2 peptide vaccine was also conducted in patients with progressive NF2-associated schwannomas, which was the first immunotherapeutic approach for NF2 patients. Targeted therapies for the gene product of SH3PXD2A-HTRA1 fusion may be effective for sporadic VS. Several protein kinase inhibitors could be supportive to prevent tumor progression because merlin inhibits signaling by tyrosine receptor kinases and the activation of downstream pathways, including the Ras/Raf/MEK/ERK and PI3K/Akt/mTORC1 pathways. Tumor-microenvironment-targeted therapy may be supportive for the mainstays of management. The tumor-associated macrophage is the major component of immunosuppressive cells in schwannomas. Here, we present a critical overview of targeted therapies for VS. Multimodal therapy is required to manage patients with refractory VS.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] Targeted therapies in bladder cancer: an overview of in vivo research
    Kim E. M. van Kessel
    Tahlita C. M. Zuiverloon
    Arnout R. Alberts
    Joost L. Boormans
    Ellen C. Zwarthoff
    Nature Reviews Urology, 2015, 12 : 681 - 694
  • [32] Companion Diagnostic Testing for Targeted Cancer Therapies: An Overview
    Fan, Yao-Shan
    GENETIC TESTING AND MOLECULAR BIOMARKERS, 2013, 17 (07) : 515 - 523
  • [33] Targeted cancer therapies; FDA approval overview.
    Cortazar, P.
    Keegan, P.
    Justice, R. L.
    Johnson, J. R.
    Pazdur, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Targeted therapies in bladder cancer: an overview of in vivo research
    van Kessel, Kim E. M.
    Zuiverloon, Tahlita C. M.
    Alberts, Arnout R.
    Boormans, Joost L.
    Zwarthoff, Ellen C.
    NATURE REVIEWS UROLOGY, 2015, 12 (12) : 681 - 694
  • [35] Overview of thioredoxin system and targeted therapies for acute leukemia
    Xie, Weiling
    Ma, Weijie
    Liu, Pan
    Zhou, Fuling
    MITOCHONDRION, 2019, 47 : 38 - 46
  • [36] Editorial: Targeted Therapies for Glioblastoma: A Critical Appraisal
    Gupta, Shiv K.
    Kizilbash, Sani H.
    Daniels, David J.
    Sarkaria, Jann N.
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [37] Vestibular Migraine Following Radiosurgery for Vestibular Schwannoma
    Chae, Ricky
    McDermott, Michael
    Muacevic, Alexander
    Adler, John R., Jr.
    Sharon, Jeffrey D.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (06)
  • [38] Electrical Vestibular Stimulation after Vestibular Deafferentation and in Vestibular Schwannoma
    Aw, Swee Tin
    Todd, Michael John
    Lehnen, Nadine
    Aw, Grace Elizabeth
    Weber, Konrad Peter
    Eggert, Thomas
    Halmagyi, Gabor Michael
    PLOS ONE, 2013, 8 (12):
  • [39] Targeted Therapies in the Treatment of Vestibular Schwannomas: Current State and New Horizons
    Welling, D. Bradley
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2023, 56 (03) : 543 - 556
  • [40] Proteomic Analysis of Vestibular Schwannoma: Conflicting Role of Apoptosis on the Pathophysiology of Sporadic Vestibular Schwannoma
    Seo, Jae-Hyun
    Park, Kyoung-Ho
    Jeon, Eun-Ju
    Chang, Ki-Hong
    Lee, Heejin
    Lee, Weonsun
    Park, Yong-Soo
    OTOLOGY & NEUROTOLOGY, 2015, 36 (04) : 714 - 719